Skip to content

Cryotherapy for Neuropathy in Children

Effect of Cryotherapy in Controlling Peripheral Neuropathy in Cancer Children

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04536207
Enrollment
60
Registered
2020-09-02
Start date
2022-02-01
Completion date
2022-07-15
Last updated
2021-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

Cancer, Peripheral neuropathy, Cryotherapy

Brief summary

This study aimed to assess the efficacy of cryotherapy in controlling Peripheral Neuropathy in cancer children

Detailed description

Peripheral neuropathy is a serious condition characterized by symmetrical, distal damage to the peripheral nerves that may be caused by several classes of drugs, including chemotherapeutic agents. Chemotherapy-induced peripheral neuropathy (CIPN) is an adverse effect estimated to occur in up to 40% of patients undergoing chemotherapy, with its incidence increasing in patients being treated with multiple agents. Pharmacists play a pivotal role in the prevention and management of CIPN by recommending evidence-based pharmacologic and non pharmacologic strategies appropriate for the individual patient.Peripheral neuropathy (PN) is a systemic disease characterized by symmetrical, distal damage to the peripheral nerves that negatively impacts patient quality of life (QOL). Prolonged symptoms associated with PN can cause pain, interfere with functional ability (e.g., dressing, driving, house-work), and disrupt emotional health.

Interventions

OTHERCryotherapy (apparatus)

Cryotherapy is a pain treatment that uses a method of localized freezing temperatures to deaden an irritated nerve. Cryotherapy is also used as a method of treating localized areas of some cancers (called cryosurgery), such as prostate cancer and to treat abnormal skin cells by dermatologists

Sponsors

South Valley University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Masking description

Single (Outcomes Assessor) Blinding process to participants and care providers was impossible due to the nature of intervention therapy. Data were analyzed by an impartial statistician (outcomes assessor), referring to each arm with an encoded name: Group A (control group) and Group B (study group).

Intervention model description

They were assigned randomly into two equal groups.Group (A) study group received the same medical care and cryotherapy, three times / weak for three successful months. And group (B) control group received medical care and standard chemotherapy only.

Eligibility

Sex/Gender
ALL
Age
8 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

1. Their age will ranging from eight to seventeen years. 2. Children participated in this study will from both sexes. 3. Children receiving chemotherapy as medical treatment protocol 4. All children have polyneuropathy caused by chemotherapy.

Exclusion criteria

1. Children with Epilepsy. 2. Children with blood clotting disorder. 3. Children have Open wounds / broken skin 4. Children with severe cardiac disease 5. Uncooperative patients.

Design outcomes

Primary

MeasureTime frameDescription
Nerve conduction studies (NCS)nerve conduction velocity for sensory ulnar nerve at day 0nerve conduction velocity for sensory ulnar nerve

Countries

Egypt

Contacts

Primary ContactNehad A. Abo-Zaid, Ph.D
dr.nehadahmed@svu.edu.eg+201223265216
Backup ContactMohammed E Ali, Ph.D student
m.essam@svu.edu.eg+201011212425

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026